Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.

Alzheon, a US-based neurodegenerative disorder treatment developer backed by pharmaceutical firm Aptus Therapeutics,┬áhas withdrawn its second attempt at an initial public offering on the Nasdaq Global Market. The company was initially looking to raise approximately $40m in its second IPO attempt after setting the price range between $15 and $16m in August 2018, but shortly…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.